Novartis is buying the Japanese generics unit of South Africa’s Aspen Pharmacare in a deal worth up to 400 million euros ($440.80 million) to expand in the world’s third-biggest drug market. “The acquisition of Aspen’s Japanese operations would significantly strengthen our position in this country, a stable but growing generics market,” Sandoz Chief Executive Richard Saynor said in a statement.

(Moneycontrol)